The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Rabies Vaccine for Humans Market Research Report 2025
Synopsis
Rabies Vaccine is an immunization drug used to prevent rabies in people who have been bitten by an animal or otherwise exposed to the rabies virus.
There are a number of rabies vaccines available that are both safe and effective. They can be used to prevent rabies, before or after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
The global Rabies Vaccine for Humans market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Rabies Vaccine for Humans, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rabies Vaccine for Humans.
Report Scope
The Rabies Vaccine for Humans market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rabies Vaccine for Humans market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rabies Vaccine for Humans manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Sanofi
GlaxoSmithKline
Merck
Chengda
Yisheng
Prcmise
VACN
Changsheng
BCHT
Hissen
Segment by Type
Preventative Vaccine
Emergency Rabies Vaccine
Segment by Application
Pre-exposure prophylaxis
Post-exposure prophylaxis
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rabies Vaccine for Humans manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rabies Vaccine for Humans in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Rabies Vaccine is an immunization drug used to prevent rabies in people who have been bitten by an animal or otherwise exposed to the rabies virus.
There are a number of rabies vaccines available that are both safe and effective. They can be used to prevent rabies, before or after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
The global Rabies Vaccine for Humans market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Rabies Vaccine for Humans, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rabies Vaccine for Humans.
Report Scope
The Rabies Vaccine for Humans market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rabies Vaccine for Humans market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rabies Vaccine for Humans manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Sanofi
GlaxoSmithKline
Merck
Chengda
Yisheng
Prcmise
VACN
Changsheng
BCHT
Hissen
Segment by Type
Preventative Vaccine
Emergency Rabies Vaccine
Segment by Application
Pre-exposure prophylaxis
Post-exposure prophylaxis
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rabies Vaccine for Humans manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rabies Vaccine for Humans in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Rabies Vaccine for Humans Market Overview
1.1 Product Overview and Scope of Rabies Vaccine for Humans
1.2 Rabies Vaccine for Humans Segment by Type
1.2.1 Global Rabies Vaccine for Humans Market Value Comparison by Type (2024-2030)
1.2.2 Preventative Vaccine
1.2.3 Emergency Rabies Vaccine
1.3 Rabies Vaccine for Humans Segment by Application
1.3.1 Global Rabies Vaccine for Humans Market Value by Application: (2024-2030)
1.3.2 Pre-exposure prophylaxis
1.3.3 Post-exposure prophylaxis
1.4 Global Rabies Vaccine for Humans Market Size Estimates and Forecasts
1.4.1 Global Rabies Vaccine for Humans Revenue 2019-2030
1.4.2 Global Rabies Vaccine for Humans Sales 2019-2030
1.4.3 Global Rabies Vaccine for Humans Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Rabies Vaccine for Humans Market Competition by Manufacturers
2.1 Global Rabies Vaccine for Humans Sales Market Share by Manufacturers (2019-2024)
2.2 Global Rabies Vaccine for Humans Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Rabies Vaccine for Humans Average Price by Manufacturers (2019-2024)
2.4 Global Rabies Vaccine for Humans Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Rabies Vaccine for Humans, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rabies Vaccine for Humans, Product Type & Application
2.7 Rabies Vaccine for Humans Market Competitive Situation and Trends
2.7.1 Rabies Vaccine for Humans Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rabies Vaccine for Humans Players Market Share by Revenue
2.7.3 Global Rabies Vaccine for Humans Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rabies Vaccine for Humans Retrospective Market Scenario by Region
3.1 Global Rabies Vaccine for Humans Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Rabies Vaccine for Humans Global Rabies Vaccine for Humans Sales by Region: 2019-2030
3.2.1 Global Rabies Vaccine for Humans Sales by Region: 2019-2024
3.2.2 Global Rabies Vaccine for Humans Sales by Region: 2025-2030
3.3 Global Rabies Vaccine for Humans Global Rabies Vaccine for Humans Revenue by Region: 2019-2030
3.3.1 Global Rabies Vaccine for Humans Revenue by Region: 2019-2024
3.3.2 Global Rabies Vaccine for Humans Revenue by Region: 2025-2030
3.4 North America Rabies Vaccine for Humans Market Facts & Figures by Country
3.4.1 North America Rabies Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Rabies Vaccine for Humans Sales by Country (2019-2030)
3.4.3 North America Rabies Vaccine for Humans Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Rabies Vaccine for Humans Market Facts & Figures by Country
3.5.1 Europe Rabies Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Rabies Vaccine for Humans Sales by Country (2019-2030)
3.5.3 Europe Rabies Vaccine for Humans Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rabies Vaccine for Humans Market Facts & Figures by Country
3.6.1 Asia Pacific Rabies Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Rabies Vaccine for Humans Sales by Country (2019-2030)
3.6.3 Asia Pacific Rabies Vaccine for Humans Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Rabies Vaccine for Humans Market Facts & Figures by Country
3.7.1 Latin America Rabies Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Rabies Vaccine for Humans Sales by Country (2019-2030)
3.7.3 Latin America Rabies Vaccine for Humans Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rabies Vaccine for Humans Market Facts & Figures by Country
3.8.1 Middle East and Africa Rabies Vaccine for Humans Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Rabies Vaccine for Humans Sales by Country (2019-2030)
3.8.3 Middle East and Africa Rabies Vaccine for Humans Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rabies Vaccine for Humans Sales by Type (2019-2030)
4.1.1 Global Rabies Vaccine for Humans Sales by Type (2019-2024)
4.1.2 Global Rabies Vaccine for Humans Sales by Type (2025-2030)
4.1.3 Global Rabies Vaccine for Humans Sales Market Share by Type (2019-2030)
4.2 Global Rabies Vaccine for Humans Revenue by Type (2019-2030)
4.2.1 Global Rabies Vaccine for Humans Revenue by Type (2019-2024)
4.2.2 Global Rabies Vaccine for Humans Revenue by Type (2025-2030)
4.2.3 Global Rabies Vaccine for Humans Revenue Market Share by Type (2019-2030)
4.3 Global Rabies Vaccine for Humans Price by Type (2019-2030)
5 Segment by Application
5.1 Global Rabies Vaccine for Humans Sales by Application (2019-2030)
5.1.1 Global Rabies Vaccine for Humans Sales by Application (2019-2024)
5.1.2 Global Rabies Vaccine for Humans Sales by Application (2025-2030)
5.1.3 Global Rabies Vaccine for Humans Sales Market Share by Application (2019-2030)
5.2 Global Rabies Vaccine for Humans Revenue by Application (2019-2030)
5.2.1 Global Rabies Vaccine for Humans Revenue by Application (2019-2024)
5.2.2 Global Rabies Vaccine for Humans Revenue by Application (2025-2030)
5.2.3 Global Rabies Vaccine for Humans Revenue Market Share by Application (2019-2030)
5.3 Global Rabies Vaccine for Humans Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Rabies Vaccine for Humans Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Rabies Vaccine for Humans Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GlaxoSmithKline Rabies Vaccine for Humans Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Rabies Vaccine for Humans Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Chengda
6.5.1 Chengda Corporation Information
6.5.2 Chengda Description and Business Overview
6.5.3 Chengda Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Chengda Rabies Vaccine for Humans Product Portfolio
6.5.5 Chengda Recent Developments/Updates
6.6 Yisheng
6.6.1 Yisheng Corporation Information
6.6.2 Yisheng Description and Business Overview
6.6.3 Yisheng Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Yisheng Rabies Vaccine for Humans Product Portfolio
6.6.5 Yisheng Recent Developments/Updates
6.7 Prcmise
6.6.1 Prcmise Corporation Information
6.6.2 Prcmise Description and Business Overview
6.6.3 Prcmise Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Prcmise Rabies Vaccine for Humans Product Portfolio
6.7.5 Prcmise Recent Developments/Updates
6.8 VACN
6.8.1 VACN Corporation Information
6.8.2 VACN Description and Business Overview
6.8.3 VACN Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.8.4 VACN Rabies Vaccine for Humans Product Portfolio
6.8.5 VACN Recent Developments/Updates
6.9 Changsheng
6.9.1 Changsheng Corporation Information
6.9.2 Changsheng Description and Business Overview
6.9.3 Changsheng Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Changsheng Rabies Vaccine for Humans Product Portfolio
6.9.5 Changsheng Recent Developments/Updates
6.10 BCHT
6.10.1 BCHT Corporation Information
6.10.2 BCHT Description and Business Overview
6.10.3 BCHT Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.10.4 BCHT Rabies Vaccine for Humans Product Portfolio
6.10.5 BCHT Recent Developments/Updates
6.11 Hissen
6.11.1 Hissen Corporation Information
6.11.2 Hissen Rabies Vaccine for Humans Description and Business Overview
6.11.3 Hissen Rabies Vaccine for Humans Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Hissen Rabies Vaccine for Humans Product Portfolio
6.11.5 Hissen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rabies Vaccine for Humans Industry Chain Analysis
7.2 Rabies Vaccine for Humans Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rabies Vaccine for Humans Production Mode & Process
7.4 Rabies Vaccine for Humans Sales and Marketing
7.4.1 Rabies Vaccine for Humans Sales Channels
7.4.2 Rabies Vaccine for Humans Distributors
7.5 Rabies Vaccine for Humans Customers
8 Rabies Vaccine for Humans Market Dynamics
8.1 Rabies Vaccine for Humans Industry Trends
8.2 Rabies Vaccine for Humans Market Drivers
8.3 Rabies Vaccine for Humans Market Challenges
8.4 Rabies Vaccine for Humans Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
